NASDAQ:GELS Gelteq (GELS) Stock Price, News & Analysis $0.47 -0.01 (-1.90%) As of 09:37 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Gelteq Stock (NASDAQ:GELS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gelteq alerts:Sign Up Key Stats Today's Range$0.48▼$0.4850-Day Range$0.48▼$0.9052-Week Range$0.39▼$2.01Volume1,975 shsAverage Volume2.41 million shsMarket Capitalization$5.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Gelteq Limited is an Australian health and wellness company that develops oral delivery products using its proprietary gel-based technology. The platform is designed to deliver active ingredients in an easy-to-consume format and may be used for nutraceutical, pharmaceutical, and other health-related applications. The company works with brand owners and other commercial partners to formulate and manufacture products such as dietary supplements, vitamins, minerals, and other functional health products. Its technology is intended to support the delivery of ingredients that may be difficult to provide through conventional tablets, capsules, or powders. Gelteq is headquartered in Australia and has positioned its business to serve customers in international markets through product development, formulation, and commercialization partnerships. The company’s shares trade on the Nasdaq Capital Market under the symbol GELS.AI Generated. May Contain Errors. Read More Gelteq Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreGELS MarketRank™: 0.5476566614 of 5 starsGelteq scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGelteq has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGelteq has only been the subject of 1 research reports in the past 90 days.Read more about Gelteq's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioGelteq has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.86% of the float of Gelteq has been sold short.Short Interest Ratio / Days to CoverGelteq has a short interest ratio ("days to cover") of 0.16, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gelteq has recently increased by 138.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGelteq does not currently pay a dividend.Dividend GrowthGelteq does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.60 News SentimentGelteq has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Gelteq this week, compared to 2 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gelteq insiders have not sold or bought any company stock.Percentage Held by InstitutionsGelteq has minimal institutional ownership at this time.Read more about Gelteq's insider trading history. Receive GELS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gelteq and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GELS Stock News HeadlinesGelteq Limited (NASDAQ:GELS) Stock Short Interest Report for SeptemberOctober 13 at 6:02 AM | americanbankingnews.comCould Gelteq’s (GELS) Gel Improve Oral Drug Delivery?October 9, 2026 | finance.yahoo.comHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling shares or trading options, but simply by holding the fund and letting it pay out cash every Thursday. That works out to a 34% annualized distribution rate, even though the underlying AI stocks pay no dividends themselves. Tim Plaehn, Chief Income Strategist at Investors Alley, breaks down exactly how the fund generates these weekly payouts.October 14 at 1:00 AM | Investors Alley (Ad)Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel TechnologyJuly 2, 2026 | stockhouse.comGelteq Limited Advances Clinical Programs and Asia Expansion in First Half of 2026June 30, 2026 | tipranks.comGelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple ProgramsJune 17, 2026 | globenewswire.comGelteq Limited: Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq Technology for Animal Health ApplicationsJune 13, 2026 | finanznachrichten.deWhat's going on with Gelteq stock Friday?June 12, 2026 | msn.comSee More Headlines GELS Stock Analysis - Frequently Asked Questions How have GELS shares performed this year? Gelteq's stock was trading at $0.80 at the beginning of 2026. Since then, GELS stock has decreased by 41.1% and is now trading at $0.4710. When did Gelteq IPO? Gelteq (GELS) raised $5 million in an IPO on Tuesday, October 29th 2024. The company issued 1,300,000 shares at $4.00 per share. The Benchmark Company served as the underwriter for the IPO. How do I buy shares of Gelteq? Shares of GELS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/14/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 4 weeks, GELS's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GELS Previous SymbolNASDAQ:GELS CIK1920092 Webwww.gelteq.com Phone61-3-9087-3990FaxN/AEmployees18Year Founded2018Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$110 thousand Price / Sales45.86 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book0.44Miscellaneous Outstanding Shares10,710,000Free FloatN/AMarket Cap$5.04 million OptionableN/A Beta-0.41 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:GELS) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Play Kevin O'Leary Is BackingKevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...The Tomorrow Investor | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredTrump's crypto bank just got approvedLast month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...Crypto 101 Media | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredAI Microcap Teams With Gentex on Next-Gen Military HelmetsMorgan Stanley projects the humanoid robotics market could reach $5 trillion by 2050, with more than 1 billion...Capital Trends | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
